Medicamen Organics
MEDIORG NSE
Medicamen Organics
HealthcareNSE: MEDIORG Pharmaceuticals
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹29.14 Cr
Volatility
Moderate
P/E Ratio
-9.3
EBITDA
₹-3.75 Cr
Return on Equity
13.28%
Debt to Equity
0.5
Book Value
₹25.69
52W High
₹38
52W Low
₹19.1
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Stock is trading at 1.01 times its book value
Weaknesses
6- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -6.38%
- Company has a low return on equity of 3.01% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 300 days.
- Working capital days have increased from 144 days to 223 days
Growth Rate
Revenue Growth
-40.91% lower than
3Y
Net Income Growth
-232% higher than
3Y
Cash Flow Change
-24.04% higher than
3Y
ROE
-22.79% lower than
3Y
ROCE
-38.67% level than
3Y
EBITDA Margin (Avg.)
-195% lower than
3Y
Quarterly Results
| Particulars | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 13.95 | 16.61 | 21.58 | 17.85 | 4.78 |
| Expenses | 11.62 | 13.88 | 17.73 | 14.43 | 11.95 |
| Operating Profit | 2.33 | 2.73 | 3.85 | 3.42 | -7.17 |
| OPM % | 16.7% | 16.44% | 17.84% | 19.16% | -150% |
| Other Income | 0.01 | 0.04 | 0.05 | 0.06 | 0.02 |
| Interest | 0.36 | 0.22 | 0.29 | 0.33 | 0.38 |
| Depreciation | 0.36 | 0.36 | 0.37 | 0.41 | 0.48 |
| PBT | 1.62 | 2.19 | 3.24 | 2.74 | -8.01 |
| Tax % | 22.84% | 30.59% | 21.6% | 25.55% | -24.47% |
| Net Profit | 1.26 | 1.51 | 2.54 | 2.04 | -6.06 |
| EPS in Rs | 1.47 | 1.29 | 2.17 | 1.74 | -4.98 |
Profit & Loss
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 25.27 | 38.19 | 22.63 |
| Expenses | 20.53 | 31.58 | 26.38 |
| Operating Profit | 4.74 | 6.61 | -3.75 |
| OPM % | 18.76% | 17.31% | -16.57% |
| Other Income | 1.07 | 0.1 | 0.08 |
| Interest | 0.65 | 0.54 | 0.71 |
| Depreciation | 0.72 | 0.74 | 0.9 |
| PBT | 4.44 | 5.43 | -5.28 |
| Tax % | 40.77% | 25.41% | -23.86% |
| Net Profit | 2.62 | 4.05 | -4.02 |
| EPS in Rs | 3.05 | 3.46 | -3.3 |
| Div. Payout % | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 8.6 | 11.7 | 12.17 |
| Reserves | 6.66 | 18.43 | 16.56 |
| Borrowings | 12.66 | 12.35 | 14.3 |
| Other Liabilities | 10.52 | 16.73 | 8.6 |
| Total Liabilities | 38.44 | 59.21 | 51.63 |
| Fixed Assets | 10.35 | 10.13 | 13.37 |
| CWIP | 0.15 | 2.22 | 0.09 |
| Investments | 0 | 0 | 0 |
| Other Assets | 27.94 | 46.86 | 38.17 |
| Total Assets | 38.44 | 59.21 | 51.63 |
Cash Flow
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Operating | -3.66 | -4.54 | -4.6 |
| Investing | -0.34 | -2.35 | -1.72 |
| Financing | 4.01 | 10.47 | 3.48 |
| Net Cash Flow | 0.01 | 3.58 | -2.83 |
| Free Cash Flow | -4.01 | -6.99 | -6.34 |
| CFO/OP | -73 | -67 | 119 |
Ratios
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Debtor Days | 241 | 247 | 300 |
| Inventory Days | 244 | 228 | 243 |
| Days Payable | 282 | 357 | 129 |
| Cash Conversion Cycle | 204 | 119 | 415 |
| Working Capital Days | 74.24 | 135 | 223 |
| ROCE % | — | 16.88% | -10.66% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Medicamen Organics insights
55 extracted metrics + investor summaries across FY22–FY26.
Documents
1
Trading Window
2 Sep - Trading window closes from October 1, 2026 until 48 hours after September 30, 2026 financial results. 2 Sep - Trading window closes from October 1, 2026 until 48 hours after September 30, 2026 financial results.
2
General Updates
2 Sep - AGM notice and FY2025-26 annual report shared; AGM on September 25, 2026 via VC/OAVM. 2 Sep - AGM notice and FY2025-26 annual report shared; AGM on September 25, 2026 via VC/OAVM.
3
Copy of Newspaper Publication
1 Sep - Published newspaper ads for 31st AGM on September 25, 2026; e-voting September 22-24, cutoff September 18. 1 Sep - Published newspaper ads for 31st AGM on September 25, 2026; e-voting September 22-24, cutoff September 18.
4
Shareholders meeting
31 Aug - FY2025-26 annual report filed; 31st AGM on September 25, 2026 via VC/OAVM. 31 Aug - FY2025-26 annual report filed; 31st AGM on September 25, 2026 via VC/OAVM.
5
Copy of Newspaper Publication
30 Aug - Newspaper ads published for 31st AGM on September 25, 2026; notice and annual report available online. 30 Aug - Newspaper ads published for 31st AGM on September 25, 2026; notice and annual report available online.
Frequently Asked Questions about Medicamen Organics
What does Medicamen Organics Ltd do?
Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage[1]
Where is Medicamen Organics Ltd (MEDIORG) listed?
Medicamen Organics Ltd trades as MEDIORG on the NSE.
Which sector does Medicamen Organics Ltd belong to?
Medicamen Organics Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Medicamen Organics Ltd?
Medicamen Organics Ltd has a market capitalisation of ₹29.14 Cr, which places it in the Small Cap band.
What is the PE ratio of Medicamen Organics Ltd?
Medicamen Organics Ltd trades at a PE ratio of -9.30, against a book value of ₹25.69 per share.
What is the 52-week high and low of Medicamen Organics Ltd?
Over the last 52 weeks Medicamen Organics Ltd has traded between ₹19.1 and ₹38.
What is the Return on Equity (ROE) of Medicamen Organics Ltd?
Medicamen Organics Ltd reported a return on equity of 13.28%. Its debt-to-equity ratio is 0.50.
Company Information
Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MEDIORG.md for Medicamen Organics Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.